JAK2 and acquired polycythemia vera: Our results indicate that ropeginterferon alfa-2b can effectively reduce HCT, WBC counts, PLT counts, and JAK2 V617F allele burden, reducing phlebotomy requirements, in Japanese patients with low-risk PV.